Drug profile · INN
casirivimab and imdevimab
RONAPREVE (NOTE 2) INITIAL APPROVAL
casirivimab and imdevimab (RONAPREVE (NOTE 2) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
PMDA: approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — casirivimab and imdevimab
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.78
Quick answer
casirivimab and imdevimab (RONAPREVE (NOTE 2) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN casirivimab and imdevimab
Brand RONAPREVE (NOTE 2) INITIAL APPROVAL
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Pipeline programs
Frequently asked questions
What is casirivimab and imdevimab?
casirivimab and imdevimab (RONAPREVE (NOTE 2) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for casirivimab and imdevimab?
RONAPREVE (NOTE 2) INITIAL APPROVAL is a marketed brand name for casirivimab and imdevimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.